Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes -: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) -: Response to Tseng

被引：0
|
作者：
Poulter, NR
Sever, PS
Dahlöf, B
Wedel, H
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Int Ctr Circulatory Hlth, Natl Heart & Lung Inst, Fac Med, London W2 1PG, England
[2] Sahlgrenska Univ Hosp Ostra, Gothenburg, Sweden
[3] Nordiska Halsovardshagskolan, Gothenburg, Sweden
来源：
DIABETES CARE | 2005年 / 28卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2595 / 2596
页数：2
相关论文
共 36 条
  • [1] Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes:: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)
    Sever, PS
    Poulter, NR
    Dahlöf, B
    Wedel, H
    Collins, R
    Beevers, G
    Caulfield, M
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Ostergren, J
    DIABETES CARE, 2005, 28 (05) : 1151 - 1157
  • [2] Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): Results in the subgroup of patients with diabetes
    Sever, PS
    Dahlof, B
    Poulter, N
    Wedel, H
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 529A - 529A
  • [3] Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)
    Sever, PS
    Poulter, NR
    Dahlöf, B
    Wedel, H
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (5A): : 39F - 44F
  • [4] Prevention of coronary and stroke events with atorvastatin in hypertensive patients - ASCOT-LLA (the Anglo-Scandinavian cardiac outcomes trial - Lipid lowering arm)
    Lyakishev, AA
    KARDIOLOGIYA, 2003, 43 (05) : 75 - 75
  • [5] Do statins lower blood pressure? Evidence from the anglo-scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA)
    Poulter, N
    Sever, PS
    CIRCULATION, 2004, 110 (17) : 402 - 402
  • [6] Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events:: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA)
    Lindgren, P
    Buxton, M
    Kahan, T
    Poulter, NR
    Dahlöf, B
    Sever, PS
    Wedel, H
    Jönsson, B
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2005, 12 (01): : 29 - 36
  • [7] Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA)
    Poulter, NR
    Dahlof, B
    Sever, PS
    Wedel, H
    Collier, D
    STROKE, 2006, 37 (02) : 695 - 695
  • [8] Anglo-scandinavian cardiac outcomes trial: Lipid lowering arm (ASCOT LLA) revisited: Interaction of antihypertensive and lipid lowering therapy
    Sever, PS
    Dahlof, B
    Poulter, NR
    Wedel, H
    CIRCULATION, 2005, 112 (17) : U188 - U188
  • [9] Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial
    Peter S Sever
    Björn Dahlöf
    Neil R Poulter
    Hans Wedel
    Gareth Beevers
    Mark Caulfield
    Rory Collins
    Sverre E Kjeldsen
    Arni Kristinsson
    Gordon T McInnes
    Jesper Mehlsen
    Markku Nieminen
    Eoin O’Brien
    Jan Östergren
    Drugs, 2004, 64 : 43 - 60
  • [10] Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -: Lipid lowering arm (ASCOT-LLA):: A multicentre randomised controlled trial
    Sever, PS
    Dahlöf, B
    Poulter, NR
    Wedel, H
    Beevers, G
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    DRUGS, 2004, 64 (Suppl 2) : 43 - 60
1234